natgillin/translations-raw huggingface dataset:
Confirmed HCV ≥ 25 IU/mL after HCV RNA &lt; 25 IU/mL during treatment, confirmed 1 log10 IU/mL increase in HCV RNA from nadir, or HCV RNA persistently ≥ 25 IU/mL with at least 6 weeks of treatment.
Potvrđena razina HCV-a od ≥ 25 IU/ml nakon što je HCV RNK tijekom liječenja bio &lt; 25 IU/ml, potvrđeno povećanje HCV RNK od 1 log10 IU/ml u odnosu na najnižu zabilježenu vrijednosti (nadir) ili postojana razina HCV RNK od ≥ 25 IU/ml uz najmanje 6 tjedana liječenja.
Confirmed hypoglycaemia was defined as episodes confirmed by plasma glucose &lt; 3.1 mmol/L or by the patient needing third party assistance.
Potvrđena hipoglikemija definirana je kao epizoda potvrđena razinom glukoze u plazmi &lt; 3,1 mmol/l ili time što je bolesniku potrebna pomoć druge osobe.
Confirmed PSA decline of 50% or 90% were 54.0% and 24.8%, respectively, for patients treated with enzalutamide and 1.5% and 0.9%, respectively, for patients who received placebo (p &lt; 0.0001).
Potvrđeno sniženje PSA za 50% odnosno 90% bilo je prisutno u 54,0% odnosno 24,8% bolesnika liječenih enzalutamidom i u 1,5% odnosno 0,9% bolesnika koji su primali placebo (p &lt; 0,0001).
Consider interruption of Tecfidera in patients with lymphocyte counts &lt; 0.5x109/L persisting for more than 6 months.
Razmotrite prekid primjene Tecfidere u bolesnika s brojem limfocita &lt; 0,5x109/L koji traje dulje od 6 mjeseci.
Consideration should also be given to interrupting treatment with tenofovir disoproxil fumarate in adult patients with creatinine clearance decreased to &lt; 50 ml/min or decreases in serum phosphate to &lt; 1.0 mg/dl (0.32 mmol/l).
Također treba razmotriti mogućnost prekida liječenja tenofovirdizoproksilfumaratom u odraslih pacijenata u kojih je klirens kreatinina smanjen na &lt; 50 ml/min ili u kojih je fosfat u serumu snižen na &lt; 1,0 mg/dl (0,32 mmol/l).
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently &lt; 100,000/mm3 .
U bolesnika koji razviju trombocitopeniju, tj. kada je broj trombocita kontinuirano &lt; 100 x 109/l, valja razmotriti mogućnost povremenih prekida primjene ili smanjenja doze filgrastima &lt; 100.000/mm3 .
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently &lt; 100,000/mm3.
Potrebno je razmotriti povremeni prekid primjene ili smanjenje doze filgrastima u bolesnika koji razviju trombocitopeniju, tj. stalno imaju broj trombocita &lt; 100 000/mm³.
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently &lt; 100,000/mm3.
Potrebno je razmotriti povremeni prekid primjene ili sniženje doze filgrastima u bolesnika koji razviju trombocitopeniju, tj. kod kojih je broj trombocita trajno &lt; 100 000/mm3.
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently &lt; 100,000/mm3.
U bolesnika koji razviju trombocitopeniju, tj. kada je broj trombocita kontinuirano &lt; 100 000/mm3, potrebno je razmotriti mogućnost povremenih prekida primjene ili smanjenja doze filgrastima.
Consideration should be given to interrupting treatment with Emtricitabine/Tenofovir disoproxil Zentiva in patients with creatinine clearance decreased to &lt; 50 ml/min or decreases in serum phosphate to &lt; 1.0 mg/dL (0.32 mmol/l).
Treba razmotriti mogućnost prekida liječenja lijekom Emtricitabine/Tenofovir disoproxil Zentiva u bolesnika u kojih je klirens kreatinina smanjen na &lt; 50 ml/min ili im je vrijednost fosfata u serumu snižena na &lt; 1,0 mg/dl (0,32 mmol/l).
Consideration should be given to interrupting treatment with Truvada in patients with creatinine clearance decreased to &lt; 50 mL/min or decreases in serum phosphate to &lt; 1.0 mg/dL (0.32 mmol/L).
Također treba razmotriti mogućnost prekida liječenja Truvadom u pacijenata u kojih je klirens kreatinina smanjen na &lt; 50 mL/min ili u kojih su fosfati u serumu sniženi na &lt; 1,0 mg/dL (0,32 mmol/L).
Consideration should be given to interrupting use of with Truvada in individuals with creatinine clearance decreased to &lt; 60 mL/min or decreases in serum phosphate to &lt; 1.0 mg/dL (0.32 mmol/L).
Treba razmotriti mogućnost prekida primjene Truvade u osoba u kojih je klirens kreatinina smanjen na &lt; 60 mL/min ili su fosfati u serumu sniženi na &lt; 1,0 mg/dl (0,32 mmol/L).
Consideration should be given to the use of a reduced infusion rate for the first infusion in these patients or a split dosing over two days during the first cycle and any subsequent cycles if the lymphocyte count is still &gt; 25 x 109/L.
U tih bolesnika treba razmotriti smanjenje brzine infuzije pri primjeni prve doze ili raspodjelu doziranja u dva dana tijekom prvog ciklusa, ali i bilo kojeg sljedećeg ciklusa ako je broj limfocita i dalje &gt; 25 x 109/l.
Constipation, dry skin, asthenia, muscle spasms, diarrhoea, arthralgia, abdominal pain, vomiting and peripheral oedema were observed less commonly ( &lt; 10% and ≥5%) were of mild to moderate severity, manageable and generally did not require dose reduction.
Konstipacija, suha koža, astenija, grčevi u mišićima, proljev, artralgija, bol u trbuhu, povraćanje i periferni edem rjeđe ( &lt; 10% i ≥5%) su zapaženi i bili su blagi do umjereni s obzirom na težinu.
Constipation, dry skin, asthenia, muscle spasms, diarrhoea, arthralgia, abdominal pain, vomiting and peripheral oedema were observed less commonly ( &lt; 10% and ≥5%), were of mild to moderate severity, manageable and generally did not require dose reduction.
Konstipacija, suha koža, astenija, grčevi u mišićima, proljev, artralgija, bol u trbuhu, povraćanje i periferni edem rjeđe ( &lt; 10% i ≥5%) su zapaženi i bili su blagi do umjereni s obzirom na težinu.
Content (concentration)
&lt; Sastav (koncentracija) &gt;
Contraindication in patients with creatinine clearance &lt; 35 ml/min
Kontraindicirana je u bolesnika s klirensom kreatinina &lt; 35 ml/min
Contraindication in patients with creatinine clearance &lt; 35 ml/min
Kontraindikacija u bolesnika s klirensom kreatinina &lt; 35 ml/min
Contraindication in patients with severe hepatic impairment (with or without cirrhosis) and in patients with baseline values of hepatic aminotransferases (AST and/or ALT) &gt; 3X ULN.
Kontraindikacija kod bolesnika s teškim oštećenjem jetre (sa ili bez ciroze) i u bolesnika s početnom vrijednošću jetrenih aminotransferaza (AST i/ili ALT) &gt; 3 x od gornje granice normale.
Contrast-enhancing tumour was resected in 64 % of patients in the experimental group compared to 38 % in the control- group (p &lt; 0.0001).
Uz pomoć kontrasta tumor je reseciran u 64 % bolesnika u eksperimentalnoj skupini, u usporedbi s 38 % u kontrolnoj skupini (p &lt; 0,0001).
Conversely, patients &gt; 75 years (n=12) experienced more frequent serious adverse reactions, dose delay, dose reduction and discontinuation compared to patients ≤ 75 years (n=105) when treated with ONIVYDE+5-FU/LV in the pancreatic adenocarcinoma study.
S druge strane, bolesnici &gt; 75 godina (n=12) imali su učestalije ozbiljne nuspojave, odgađanje doze, smanjivanje doze i prekid liječenja u usporedbi s bolesnicima ≤ 75 godina (n=105) kad su primali ONIVYDE+5-FU/LV u ispitivanju adenokarcinoma gušterače.
Conversion rates at week 120 were highest (73.1%; 68/93) in patients with MDRH &amp; R-TB, 70.5% (31/44) in pre-XDR-TB patients and lowest (62.2%; 23/37) in XDR-TB patients.
Stope konverzije u tjednu 120 bile su najviše (73,1%; 68/93) u bolesnika s MDRH &amp; R-TB, 70,5% (31/44) u bolesnika s pre-XDR-TB i najniže (62,2%; 23/37) u XDR-TB bolesnika.
Conversion rates at week 24 were highest (87.1%; 81/93) in patients with MDRH &amp; R-TB, 77.3% (34/44) in pre-XDR-TB patients and lowest (54.1%; 20/37) in XDR-TB patients.
Stope konverzije u tjednu 24 bile su najveće (87,1%; 81/93) u bolesnika s MDRH &amp; R-TB,, 77,3% (34/44) u bolesnika s pre-XDR-TB i najmanje (54,1%; 20/37) u bolesnika s XDR-TB.
COPD patients with a baseline (pre-bronchodilator) FEV1 &lt; 60% of predicted normal were randomised to double-blind medication.
Bolesnici s KOPB-om i početnim (prije bronhodilatatora) FEV1 &lt; 60% predviđene normale bili su randomizirani u terapijske skupine na dvostruko slijepi način.
copies &gt; /= 25,614
&gt; /= 25614
CrCL 60-89 mL/min (n=59), moderate renal impairment, CrCL 30-59 mL/min (n=22), and severe renal impairment CrCL &lt; 30 mL/min (n=3).
CrCL ≥90 ml/min (n= 213), blagim oštećenjem funkcije bubrega, CrCL 60-89 ml/min (n= 59), umjerenim oštećenjem funkcije bubrega, CrCL 30-59 ml/min (n= 22) i teškim oštećenjem funkcije bubrega CrCL &lt; 30 ml/min (n= 3).
CrCL &lt; 15 mL/min), to use the correct Lixiana dose in patients with CrCL 15 – 50 mL/min (30 mg once daily), in patients with CrCL &gt; 50 mL/min (60 mg once daily) and when deciding on the use of Lixiana in patients with increased creatinine clearance (see section 4.4).
CrCL &lt; 15 ml/min) i primijenila ispravna doza Lixiane u bolesnika s CrCL 15 – 50 ml/min (30 mg jedanput na dan), u bolesnika s CrCL &gt; 50 ml/min (60 mg jedanput na dan) te kad se odlučuje o primjeni Lixiane u bolesnika s povećanim klirensom kreatinina (vidjeti dio 4.4).
CrCL &lt; 30 mL/min ).
CrCL &lt; 30 mL/min).
CrCL &lt; 30 mL/min) (see sections 4.3, 4.4 and 5.2).
CrCL &lt; 30 mL/min) (vidjeti dijelov 4.3, 4.4 i 5.2).
CrCL &lt; 30 mL/min) (see sections 4.3, 4.4 and 5.2).
CrCL &lt; 30 mL/min) (vidjeti dijelove 4.3, 4.4 i 5.2).
CrCl &lt; 70 mL/min (n=214)
CrCl &lt; 70 ml/min (n=214)
CrCL ≥ 30- &lt; 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate
CrCL ≥ 30 - &lt; 50 mL/min, početi VKA 2 dana prije prekida dabigatraneteksilata
CrCL ≥ 30- &lt; 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate
CrCL ≥ 30- &lt; 50 mL/min, početi VKA 2 dana prije prekida dabigatraneteksilata
Creatinine &lt; 2.5 mg/dl
Kreatinin &lt; 2,5 mg/dl
Creatinine clearance &lt; 15 mL/min (or creatinine clearance decreases to ≤ 50% of baseline) or need for dialysis
Klirens kreatinina &lt; 15 ml/min (ili klirens kreatinina smanjen na ≤ 50% od početne vrijednosti) ili potreba za dijalizom (vidjeti dio 4.4)
Creatinine increases of &gt; 50% from baseline.) and not crude adverse event report frequency.
Razina kreatinina se povećava do &gt; 50% od početne vrijednosti), a ne učestalost prijave nuspojava.
CRh* was defined as  5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt; 50,000/microlitre and ANC &gt; 500/microlitre).
CRh* je definiran kao  5% blasta u koštanoj srži, bez dokaza bolesti, uz djelomični oporavak broja stanica u perifernoj krvi (trombociti &gt; 50,000/mikrolitar i apsolutni broj neutrofila &gt; 500/mikrolitar).
Crizotinib plasma concentrations may be increased in patients with severe renal impairment (CLcr &lt; 30 mL/min).
Plazmatska koncentracija krizotiniba može biti povećana u bolesnika s teškim bubrežnim oštećenjem (CLcr &lt; 30 mL/min).
Crizotinib resulted in a significantly lower deterioration from baseline in peripheral neuropathy (Cycles 6 to 20; p-value &lt; 0.05), dysphagia (Cycles 5 to 11; p-value &lt; 0.05) and sore mouth (Cycle 2 to 20; p-value &lt; 0.05) compared to chemotherapy.
Krizotinib je rezultirao značajno manjim pogoršanjem u odnosu na početne vrijednosti kod periferne neuropatije (Ciklusi od 6. do 20.; p-vrijednost &lt; 0,05), disfagije (Ciklusi od 5. do 11.; p-vrijednost &lt; 0,05) i boli u ustima (Ciklus od 2. do 20.; p-vrijednost &lt; 0,05) u usporedbi s kemoterapijom.
Crizotinib resulted in overall global quality of life benefits with a significantly greater improvement from baseline observed in the crizotinib arm compared to the chemotherapy arm (Cycles 2 to 20; value &lt; 0.05).
Krizotinib je pokazao korist za ukupnu opću kvalitetu života sa značajnim poboljšanjem u odnosu na početne vrijednosti opaženim u skupini krizotiniba u usporedbi s kemoterapijskom skupinom (Ciklusi od 2. do 20.; p-vrijednost &lt; 0,05).
Crizotinib should not be used in patients with severe hepatic impairment (including patients with total bilirubin &gt; 3 × ULN regardless of ALT/AST) (see sections 4.2, 4.3 and 4.8).
Krizotinib se ne smije primjenjivati u bolesnika s teškim oštećenjem funkcije jetre (uključujući bolesnike s vrijednostima ukupnog bilirubina &gt; 3× GGN, bez obzira na ALT/AST) (vidjeti dijelove 4.2, 4.3 i 4.8).
Crizotinib showed a significantly greater improvement from baseline compared to chemotherapy in alopecia (Cycles 2 to 15; p-value &lt; 0.05), cough (Cycles 2 to 20; p-value &lt; 0.0001), dyspnoea (Cycles 2 to 20; p-value &lt; 0.0001), haemoptysis (Cycles 2 to 20; p-value &lt; 0.05), pain in arm or shoulder (Cycles 2 to 20; p-value &lt; 0.0001), pain in chest (Cycles 2 to 20; p-value &lt; 0.0001), and pain in other parts (Cycles 2 to 20; p-value &lt; 0.05).
Krizotinib je pokazao značajno veće poboljšanje u odnosu na početne vrijednosti u usporedbi s kemoterapijom kod alopecije (Ciklusi od 2. do 15.; p-vrijednost &lt; 0,05), kašlja (Ciklusi od 2. do 20.; p- vrijednost &lt; 0,0001), dispneje (Ciklusi od 2. do 20.; p &lt; 0,0001), hemoptize (Ciklusi od 2. do 20.; p- vrijednost &lt; 0,05), boli u ruci ili ramenu (Ciklusi od 2. do 20.; p-vrijednost &lt; 0,0001), boli u prsištu (Ciklusi od 2. do 20.; p-vrijednost &lt; 0,0001) i boli u drugim predjelima (Ciklusi od 2. do 20.; p- vrijednost &lt; 0,05).
CTC grades: neutropaenia (Grade 3 ≥ 0.5– &lt; 1.0 × 109/l, Grade 4 &lt; 0.5 × 109/l); thrombocytopaenia (Grade 3 ≥ 25 –
CTC stupnjevi: neutropenija (stupanj 3: ≥0,5– &lt; 1,0 × 109/l, stupanj 4: &lt; 0,5 × 109/l); trombocitopenija (stupanj 3:
CTCAE (version 3.0) Grade 3 hypertriglyceridaemia and angina pectoris occurred in &lt; 1% of patients.
Hipertrigliceridemija stupnja 3 prema CTCAE (verzija 3.0) i angina pectoris stupnja 4 prema CTCAE (verzija 3.0) javile su se u &lt; 1% bolesnika.
CTCAE (version 3.0) Grade 4 peripheral oedema, hypokalaemia, urinary tract infection, cardiac failure and fractures occurred in &lt; 1% of patients.
Periferni edem, hipokalemija, infekcija mokraćnih puteva, zatajivanje srca i frakture stupnja 4 prema CTCAE (verzija 3.0) nastupili su u &lt; 1% bolesnika.
CTCAEc grade 3 ( &lt; 1,000 – 500/mm3)
CTCAEc stupanj 3 ( &lt; 1000 – 500/mm3)
CTCAEc grade 3 ( &lt; 8.0 – 6.5g/dl)
CTCAEc stupanj 3 ( &lt; 8,0 – 6,5 g/dl)
CTCAEc grade 3 ( &gt; 5x – 20 x ULN)
CTCAEc stupanj 3 ( &gt; 5x – 20 x GGN)
CTCAEc grade 4 ( &lt; 25,000/mm3)
CTCAEc stupanj 4 ( &lt; 25 000/mm3)
CTCAEc grade 4 ( &lt; 500/mm3)
CTCAEc stupanj 4 ( &lt; 500/mm3)
CTCAEc grade 4 ( &lt; 6.5g/dl)
CTCAEc stupanj 4 ( &lt; 6,5 g/dl)
Cumulative urinary excretion is &lt; 1% of dose.
Kumulativna urinarna ekskrecija je &lt; 1% doze.
Cumulative urinary excretion is &lt; 1 % of dose.
Kumulativna urinarna ekskrecija je &lt; 1 % doze.
Cumulative urinary excretion is &lt; 1 % of dose.
Kumulativna urinarna ekskrecija je &lt; 1% doze.
Cumulatively, there were 4 patients who experienced a viremic episode (HBV DNA &gt; 400 copies/ml) at their last timepoint on TDF.
Kumulativno, 4 pacijenta na TDF-u imala su viremijsku epizodu (HBV DNK &gt; 400 kopija/ml) u posljednjoj vremenskoj točki.
Cushing’s disease patients with poor glycaemic control (as defined by HbA1c values &gt; 8% while receiving antidiabetic therapy) may be at higher risk of developing severe hyperglycaemia and associated complications (e.g. ketoacidosis).
Bolesnici oboljeli od Cushingove bolesti sa slabom glikemijskom kontrolom (definiranom vrijednostima HbA1c &gt; 8% dok primaju antidijabetičku terapiju) mogli bi imati veći rizik od razvoja teške hiperglikemije i povezanih komplikacija (npr. ketoacidoza).
Cymbalta 60 mg to 120 mg once daily demonstrated statistically significant superiority compared to placebo (p &lt; 0.001) on the prevention of relapse, as measured by time to relapse.
Cymbalta u dozi od 60 do 120 mg jednom dnevno bila je statistički značajno superiornija u odnosu na placebo (p &lt; 0,001) u prevenciji relapsa, mjereno vremenom do pojave relapsa.
Cymbalta must not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min; see section 4.3).
Cymbalta se ne smije primjenjivati u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina &lt; 30 ml/min; vidjeti dio 4.3).
CYP1A2 and CYP2C19 constitute minor ( &lt; 10%) pathways in axitinib metabolism.
CYP1A2 i CYP2C19 predstavljaju manje ( &lt; 10%) putove metabolizma aksitiniba.
Cystoid macular oedema has been uncommonly reported (≥1/1,000 to &lt; 1/100) following treatment with bimatoprost 0.3 mg/mL eye drops (multi-dose formulation).
Manje često je prijavljen cistoidni makularni edem (≥1/1000 do &lt; 1/100) nakon liječenja otopinom bimatoprosta 0,3 mg/ml kapi za oko (višedoznog pripravka).
Cystoid macular oedema has been uncommonly reported (≥1/1,000 to &lt; 1/100) following treatment with bimatoprost 0.3 mg/ml eye drops, solution.
Manje često je prijavljen cistoidni makularni edem (≥1/1000 do &lt; 1/100) nakon liječenja otopinom bimatoprosta 0,3 mg/ml kapi za oko.
Cystoid macular oedema has been uncommonly reported (≥1/1,000 to &lt; 1/100) following treatment with bimatoprost 0.3 mg/ml eye drops.
Manje često je prijavljen cistoidni makularni edem (≥1/1000 do &lt; 1/100) nakon liječenja otopinom bimatoprost 0,3 mg/ml kapi za oko.
Cytogenetic Response criteria: Major Cytogenetic response included Complete (0% Ph+ metaphases from bone marrow or &lt; 1% positive cells from fluorescent in situ hybridization [FISH]) or partial (1%-35%) cytogenetic responses.
Kriteriji citogenetskog odgovora: veliki citogenetski odgovor uključivao je potpune (0% Ph+ metafaza u koštanoj srži ili &lt; 1% pozitivnih stanica u fluorescentnoj in situ hibridizaciji [FISH]) ili parcijalne (1%-35%) citogenetske odgovore.
Cytogenetic responses were based on the percentage of Ph+ metaphases among &gt; /= 20 metaphase cells in each bone marrow sample.
Citogenetski odgovori su bili temeljeni na postotku Ph+ metafaza među &gt; /= 20 metafaznih stanica u svakom uzorku koštane srži.
Dabigatran etexilate can be given as soon as the International Normalized Ratio (INR) is &lt; 2.0.
Dabigatraneteksilat se može davati čim je internacionalni normalizirani omjer (INR) &lt; 2,0.
Dabrafenib has not been studied in patients with renal insufficiency (defined as creatinine &gt; 1.5 x ULN) therefore caution should be used in this setting (see section 5.2).
Dabrafenib nije ispitivan u bolesnika s bubrežnom insuficijencijom (definirana kao kreatinin &gt; 1,5 x GGN), te je stoga potreban oprez u ovakvim slučajevima (vidjeti dio 5.2).
Dabrafenib was phototoxic in an in vitro mouse fibroblast 3T3 Neutral Red Uptake (NRU) assay and in vivo at doses ≥100 mg/kg ( &gt; 44 times clinical exposure based on Cmax) in an oral phototoxicity study in hairless mice.
Dabrafenib je bio fototoksičan u in vitro testu na mišjim fibroblastima 3T3 Neutral Red Uptake (NRU) i in vivo pri dozama ≥ 100 mg/kg ( &gt; 44 puta kliničke izloženosti temeljeno na Cmax) u ispitivanju fototoksičnosti nakon peroralne primjene kod bezdlakih miševa.
Daclatasvir in vitro did not inhibit (IC50 &gt; 40 µM) CYP enzymes 1A2, 2B6, 2C8, 2C9, 2C19, or 2D6.
Daklatazvir nije inhibirao (IC50 &gt; 40 µM) enzime CYP1A2, 2B6, 2C8, 2C9, 2C19 ni 2D6 in vitro.
Daclizumab was detected in the milk of 11/14 lactating monkeys at levels that were &lt; 0.122% of the maternal serum levels, with no adverse reactions observed in the off-spring.
Daklizumab je otkriven u mlijeku 11/14 ženki majmuna u laktaciji na razinama koje su bile &lt; 0,122% od razina u serumu majke, bez nuspojava opaženih u mladunčadi.
Daily dose adjustment using Viread 33 mg/g granules is recommended for patients with severe renal impairment (creatinine clearance &lt; 30 ml/min).
Prilagodba dnevnih doza primjenom Viread 33 mg/g granula preporučuje se u pacijenata s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 30 ml/min).
Dapagliflozin 10 mg as an add-on to metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant body weight reduction at 24 weeks (p &lt; 0.0001, Tables 4 and 5).
Dapagliflozin u dozi od 10 mg kao dodatak liječenju metforminom, glimepiridom, metforminom i sulfonilurejom, sitagliptinom (sa ili bez metformina) ili inzulinom doveo je do statistički značajnog smanjenja tjelesne težine u 24 tjedna (p &lt; 0,0001, Tablice 4 i 5).
Dapagliflozin 10 mg as an add-on to metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant body weight reduction at 24 weeks (p &lt; 0.0001, Tables 4 and 5).
Dapagliflozin u dozi od 10 mg kao dodatak liječenju metforminom, glimepiridom, metforminom i sulfonilurejom, sitagliptinom (sa ili bez metformina) ili inzulinom doveo je do statistički značajnog smanjenja tjelesne težine u 24 tjedna (p &lt; 0.0001, Tablice 4 i 5).
Dapagliflozin 5 mg twice daily provided statistically significant reductions in HbA1c at 16 weeks compared with subjects receiving placebo (p &lt; 0.0001; Table 3).
Dapagliflozin u dozi od 5 mg dvaput na dan doveo je do statistički značajnih smanjenja vrijednosti HbA1c u 16. tjednu u usporedbi s ispitanicima koji su primali placebo (p &lt; 0,0001; Tablica 3)
Dapagliflozin as an add-on to metformin alone or metformin plus sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant body weight reduction up to 24 weeks (p &lt; 0.0001, Tables 3, 4 and 5).
Dapagliflozin kao dodatak liječenju metforminu samom ili u kombinaciji sa sitagliptinom, sulfonilurejom ili inzulinom (s ili bez dodatnih lijekova za snižavanje razine glukoze, uključujući metformin) doveo je do statistički značajnog smanjenja tjelesne težine u 24. tjednu. (p &lt; 0,0001, Tablica 3, 4 i 5).
Dapagliflozin as an add-on with either metformin alone, metformin in combination with sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant mean reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p &lt; 0.0001; Tables 3, 4 and 5).
Dapagliflozin kao dodatak liječenju sa metforminom samim, metforminom u kombinaciji sa sitagliptinom, sulfonilurejom ili inzulinom (s ili bez dodatnih peroralnih lijekova za snižavanje razine glukoze, uključujući metformin) doveo je do statistički značajnih srednjih smanjenja vrijednosti HbA1c u 24. tjednu u usporedbi s ispitanicima koji su primali placebo (p &lt; 0,0001; Tablice 3, 4 i 5).
Dapagliflozin as an add-on with either metformin alone, metformin in combination with sitagliptin, sulphonylurea, or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant mean reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p &lt; 0.0001; Tables 3, 4 and 5).
Dapagliflozin kao dodatak liječenju sa metforminom samim, metforminom u kombinaciji sa sitagliptinom, sulfonilurejom ili inzulinom (s ili bez dodatnih peroralnih lijekova za snižavanje razine glukoze, uključujući metformin) doveo je do statistički značajnih srednjih smanjenja vrijednosti HbA1c u 24. tjednu u usporedbi s ispitanicima koji su primali placebo (p &lt; 0,0001; Tablice 3,4 i 5).
Dapagliflozin as an add-on with either metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p &lt; 0.0001; Tables 4, 5 and 6).
Dapagliflozin pridodan liječenju metforminom, glimepiridom, metforminom i sulfonilurejom, sitagliptinom (sa ili bez metformina) ili inzulinom doveo je do statistički značajnog sniženja HbA1c u 24 tjedna u usporedbi s ispitanicima koji su primali placebo (p &lt; 0,0001; Tablice 4, 5 i 6).